-REGENERON PHARMACEUTICALS - LIBTAYO IN COMBINATION WITH CHEMOTHERAPY APPROVED BY EUROPEAN COMMISSION FOR THE FIRST-LINE TREATMENT OF ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER

Media coverage

• Title	-REGENERON PHARMACEUTICALS - LIBTAYO IN COMBINATION WITH CHEMOTHERAPY APPROVED BY EUROPEAN COMMISSION FOR THE FIRST-LINE TREATMENT OF ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
  Media name/outlet	M2 PressWIRE
  Country/Territory	United States
  Date	30/03/23
  Persons	Israel Lowy,

• Title	REGENERON PHARMACEUTICALS - LIBTAYO IN COMBINATION WITH CHEMOTHERAPY APPROVED BY EUROPEAN COMMISSION FOR THE FIRST-LINE TREATMENT OF ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
  Media name/outlet	MarketScreener.com
  Country/Territory	United States
  Date	30/03/23
  URL	https://www.marketscreener.com/quote/stock/REGENERON-PHARMACEUTICALS-10649/news/REGENERON-PHARMACEUTICALS-LIBTAYO-IN-COMBINATION-WITH-CHEMOTHERAPY-APPROVED-BY-EUROPEAN-COMMISSION-43384226/
  Persons	Israel Lowy,

• Title	-REGENERON PHARMACEUTICALS - LIBTAYO IN COMBINATION WITH CHEMOTHERAPY APPROVED BY EUROPEAN COMMISSION FOR THE FIRST-LINE TREATMENT OF ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	30/03/23
  Persons	Israel Lowy,